Two preventive tools — a maternal vaccine and a monoclonal antibody — were tied to a recent drop in RSV hospitalization rates for U.S. babies.

A single dose of the adult RSV vaccine RSVPreF3 OA prevented RSV–lower respiratory tract disease during 3 virus seasons in adults aged 60+.

Maternal RSV vaccination and nirsevimab were associated with a reduction in RSV hospitalization rates in infants aged 0 to 7 months during the 2024-2025 RSV season.

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

Recommendations supporting respiratory syncytial virus vaccines marketed by Pfizer (NYSE:PFE) and GSK (NYSE:GSK) made last ...

as the presentation is indistinguishable from other respiratory tract infections, and epidemics often overlap. The microbiologic confirmation of RSV infection is based on detecting the virus in a ...

Respiratory virus data included in the interactive data application is up-to-date as of May 10, 2025. Among its new features, the dashboard now includes RSV Severe Outcomes data.

a respiratory and public health physician from Monash University. 'Immunity wanes pretty substantially over three to six months, [but] also the virus evolves,' he told Daily Mail Australia this week.

A narrowing of the smallest airways in the lung (bronchioles) causes wheezing. This narrowing results from swelling caused by a virus. The respiratory syncytial virus (RSV) causes most bronchiolitis.

US health experts have raised concerns as the H5N1 avian flu virus rapidly propagates throughout ... died following hospitalization due to severe respiratory symptoms. According to health ...